Ivan D. Horak

17.5k total citations · 3 hit papers
205 papers, 14.0k citations indexed

About

Ivan D. Horak is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Ivan D. Horak has authored 205 papers receiving a total of 14.0k indexed citations (citations by other indexed papers that have themselves been cited), including 86 papers in Oncology, 77 papers in Molecular Biology and 58 papers in Immunology. Recurrent topics in Ivan D. Horak's work include Monoclonal and Polyclonal Antibodies Research (44 papers), Radiopharmaceutical Chemistry and Applications (31 papers) and HER2/EGFR in Cancer Research (28 papers). Ivan D. Horak is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (44 papers), Radiopharmaceutical Chemistry and Applications (31 papers) and HER2/EGFR in Cancer Research (28 papers). Ivan D. Horak collaborates with scholars based in United States, Germany and Slovakia. Ivan D. Horak's co-authors include Hubert Schorle, Anneliese Schimpl, Benjamin Sadlack, Alfred C. Feller, Hartmut Merz, Klaus‐Peter Knobeloch, Joseph B. Bolen, Eva Horak, Jürgen Löhler and Thomas Hünig and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Ivan D. Horak

201 papers receiving 13.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene

1993 1.4k citations Ivan D. Horak et al. profile →
Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting

1991 710 citations Ivan D. Horak et al. profile →
Immunodeficiency and Chronic Myelogenous Leukemia-like Syndrome in Mice with a Targeted Mutation of the ICSBP Gene

1996 547 citations Klaus‐Peter Knobeloch, Ivan D. Horak et al. profile →

Peers

Ivan D. Horak

IMMUN

ONCOL

RNMI

GENET

Hiroshi Shiku Japan

Chikao Morimoto United States

Yutaka Kawakami Japan

Günter J. Hämmerling Germany

Steven J. Burakoff United States

Benjamin Bonavida United States

Jeffrey A. Ledbetter United States

Kazuo Sugamura Japan

Steven T. Pals Netherlands

Carl J. March United States

Hiroshi Shiku Japan

Ivan D. Horak

6.6k ×1.2

IMMUN

6.7k ×1.4

4.4k ×1.1

ONCOL

1.4k ×0.8

RNMI

1.1k ×0.8

GENET

Citations per year, relative to Ivan D. Horak Ivan D. Horak (= 1×) peers Hiroshi Shiku

Countries citing papers authored by Ivan D. Horak

Since Specialization

Citations

This map shows the geographic impact of Ivan D. Horak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ivan D. Horak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ivan D. Horak more than expected).

Fields of papers citing papers by Ivan D. Horak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ivan D. Horak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ivan D. Horak. The network helps show where Ivan D. Horak may publish in the future.

Co-authorship network of co-authors of Ivan D. Horak

This figure shows the co-authorship network connecting the top 25 collaborators of Ivan D. Horak. A scholar is included among the top collaborators of Ivan D. Horak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ivan D. Horak. Ivan D. Horak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Teo, Pei Y., David H. Quach, Richard Ong, et al.. (2024). Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy. Cancer Immunology Research. 12(8). 1108–1122. 1 indexed citations

Yeo, Siok Ping, Lindsay Kua, Chek Meng Poh, et al.. (2024). B7-H3–Targeting Chimeric Antigen Receptors Epstein-Barr Virus–specific T Cells Provides a Tumor Agnostic Off-The-Shelf Therapy Against B7-H3–positive Solid Tumors. Cancer Research Communications. 4(6). 1410–1429. 3 indexed citations

Ahmed, Sairah, Matthew Mei, David M. Kurtz, et al.. (2023). Combined autologous CD30.CAR‐T cells and nivolumab in patients with relapsed or refractory classical Hodgkin Lymphoma after failure of frontline therapy (ACTION study). Hematological Oncology. 41(S2). 524–525.

Gjetting, Torben, Monika Gad, Camilla Fröhlich, et al.. (2019). Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform. mAbs. 11(4). 666–680. 25 indexed citations

Calvert, Valerie, Shruti Rao, Simina M. Boca, et al.. (2018). Acquired Resistance to a MET Antibody In Vivo Can Be Overcome by the MET Antibody Mixture Sym015. Molecular Cancer Therapeutics. 17(6). 1259–1270. 9 indexed citations

Poulsen, Thomas T., Michael M. Grandal, Klaus Koefoed, et al.. (2017). Sym015: A Highly Efficacious Antibody Mixture against MET -Amplified Tumors. Clinical Cancer Research. 23(19). 5923–5935. 42 indexed citations

Grandal, Michael M., Thomas T. Poulsen, Klaus Koefoed, et al.. (2017). Simultaneous Targeting of Two Distinct Epitopes on MET Effectively Inhibits MET- and HGF-Driven Tumor Growth by Multiple Mechanisms. Molecular Cancer Therapeutics. 16(12). 2780–2791. 23 indexed citations

Lindsted, Trine, Camilla Fröhlich, Jesper V. Olsen, et al.. (2016). Cetuximab Resistance in Squamous Carcinomas of the Upper Aerodigestive Tract Is Driven by Receptor Tyrosine Kinase Plasticity: Potential for mAb Mixtures. Molecular Cancer Therapeutics. 15(7). 1614–1626. 15 indexed citations

Jacobsen, Helle J., Thomas T. Poulsen, Anna Dahlman, et al.. (2015). Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity. Clinical Cancer Research. 21(18). 4110–4122. 71 indexed citations

10.

Dienstmann, Rodrigo, Amita Patnaik, Rocio García‐Carbonero, et al.. (2015). Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer. Cancer Discovery. 5(6). 598–609. 58 indexed citations

11.

Pedersen, Mikkel W., Helle J. Jacobsen, Klaus Koefoed, et al.. (2015). Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance. Molecular Cancer Therapeutics. 14(3). 669–680. 42 indexed citations

12.

Cook, Rebecca S., Joan T. Garrett, Violeta Sánchez, et al.. (2011). ErbB3 Ablation Impairs PI3K/Akt-Dependent Mammary Tumorigenesis. Cancer Research. 71(11). 3941–3951. 64 indexed citations

13.

Zhang, Yixian, Stephen Castaneda, Melissa Dumble, et al.. (2011). Reduced Expression of the Androgen Receptor by Third Generation of Antisense Shows Antitumor Activity in Models of Prostate Cancer. Molecular Cancer Therapeutics. 10(12). 2309–2319. 41 indexed citations

14.

Lenschow, Deborah J., Natalia Frias‐Staheli, Nadia V. Giannakopoulos, et al.. (2007). IFN-stimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses. Proceedings of the National Academy of Sciences. 104(4). 1371–1376. 436 indexed citations

15.

Lorenzi, Philip L., William C. Reinhold, Martina Rudelius, et al.. (2007). Asparagine synthetase as a causal, predictive biomarker forL-asparaginase activity in ovarian cancer cells. Molecular Cancer Therapeutics. 5(11).

16.

Sapra, Puja, et al.. (2005). Construction, characterization, and mammalian expression of an immunotoxin consisting of ranpirnase (Rap) fused to a humanized anti-EGP-1 antibody, hRS7, as a potential therapeutic for prostate cancer. Cancer Research. 65. 160–160. 2 indexed citations

17.

Menéndez, Javier A., et al.. (2005). In support of Fatty Acid Synthase (FAS) as a metabolic oncogene in breast cancer: Extracellular acidosis acts in an epigenetic fashion activating Fatty Acid Synthase (FAS) gene expression in non-cancerous human breast epithelial MCF10A and breast cancer MCF-7 cells. Cancer Research. 65. 655–655. 1 indexed citations

18.

Scher, Howard I., W.M. Kelly, Zuo‐Feng Zhang, et al.. (1999). Post-therapy Serum Prostate-Specific Antigen Level and Survival in Patients With Androgen-Independent Prostate Cancer. JNCI Journal of the National Cancer Institute. 91(3). 244–251. 140 indexed citations

19.

Autenrieth, Ingo B., et al.. (1997). Cytokine mRNA expression in intestinal tissue of interleukin-2 deficient mice with bowel inflammation. Gut. 41(6). 793–800. 56 indexed citations

20.

Štefanová, Irena, M. Wayne Saville, Christian Peters, et al.. (1996). HIV infection--induced posttranslational modification of T cell signaling molecules associated with disease progression.. Journal of Clinical Investigation. 98(6). 1290–1297. 79 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact